

Game-Changing Innovation in Wound Treatment

A Unique Opportunity in a Multi-Billion Dollar Market

The Company

The Swiss biotech and healthcare company has developed breakthrough wound care technologies through 7+ years of dedicated research and development. With strong intellectual property protection and proven clinical results, the company is now preparing for global market entry with its revolutionary technology.

Medical Expertise

- World-class wound care specialists
- International medical advisory board
- Strong operational team with pharmaceutical and healthcare industry background
- Clear focus on clinical excellence and patient outcomes

The Core Product

The flagship product represents a breakthrough in wound treatment:

- Revolutionary physical mode of action targeting prevalent wound pathogens and fungi
- No antibiotics or disinfectants
- Significantly reduces healing time
- No adverse effects
- Cost-effective application
- Strong clinical evidence
- Prevents recontamination
- Supports natural healing process

Market Opportunity

- Addressable market: > USD 14 bn (2024)
- Projected market growth to USD 24 bn by 2032
- 50 million potential patients annually worldwide
- Exclusive Distribution agreements signed with UAE, Mexico, Kuwait, Egypt and USA
- Focus areas:
 - Diabetic foot ulcers
 - Pressure ulcers
 - Burns

Competitive Advantages


- Patent protected in major markets (US, Japan, Australia; EU pending)
- FDA 510(k) clearance expected Q1 2025
- Efficacy demonstrated through observational studies
- Unique physical mode of action
- No direct competition in core technology

Game-Changing Innovation in Wound Treatment

A Unique Opportunity in a Multi-Billion Dollar Market

Financial Highlights

- Projected revenue 2029: > USD 950M
- Attractive EBITDA margins > 50% from 2027
- Scalable platform with additional product lines
- Conservative revenue projections based on single application area



Investment Opportunity

Seeking a strategic partner for global expansion:

- Investment volume: USD 10 million
- Opportunity to acquire equity stake
- Use of funds:
 - Completion of FDA clearance
 - Global production scale-up
 - US market entry
 - International marketing initiatives

Next steps

Qualified investors are invited to contact our exclusive M&A advisor for further information:

Trown Partners AG
 Florastrasse 44
 CH-8008 Zurich
 Tel: +41 44 521 04 44
 Email: info@trown.ch